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 The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly in-
creased accumulation of human genotypic, phenotypic and clinical data, and improved our under-
standing of the spectrum of clinical manifestations. As a result, the WHO disease classification of 
EVD underwent major revision. 
[H1] Former filovirus disease names 
Filoviruses, the members of the family Filoviridae, 
are currently classified into one proposed and five 
established genera (Supplementary Table 1). Of the 
twelve described filoviruses, six have been identi-
fied as etiological agents of naturally occurring hu-
man disease outbreaks. 
The International Classification of Diseases (ICD; 
Supplementary Box 1) is primarily a statistical tabu-
lation. Consequently, frequently observed diseases 
with large patient cohorts are more likely to have 
their own disease names, codes and subcategories of 
disease manifestations than uncommonly occurring 
diseases because larger cohorts ensure statistical 
reliability of disease descriptions. Given the past low 
number of filovirus disease outbreaks and overall 
case-numbers (34 disease outbreaks until 2013, 
involving 2,872 infections and 1,968 deaths), it is 
not surprising that the diseases caused by filovirus-
es were not captured by early ICD iterations. In ICD-
9, the only code defining filovirus diseases was 
“078.89 Other specified diseases due to viruses.” 
Consequently, various unofficial filovirus disease 
names have been used in the scientific literature 
(Supplementary Tables 2 and 3). 
The currently used ICD-10 recognizes filovirus 
diseases specifically via entries “A98.4 Ebola virus 
disease (EVD)” and “A98.3 Marburg virus disease 
(MVD)” (https://icd.who.int/browse10/2016/en) 
since 1994. However, the ICD-10 does not specify 
which filoviruses are considered to cause which of 
the two diseases, offer disease definitions, or ac-
count for unusual disease manifestations (for exam-
ple, subclinical or persistent infections). 
[H1] A need for new filovirus disease names  
In 2014, Ebola virus (EBOV) was identified as the 
etiological agent of an EVD outbreak in Western 
Africa in 2013–2016 that would ultimately cause at 
least 28,652 human infections and 11,325 deaths. 
This single outbreak involved almost ten times the 
combined number of patients from all previous filo-
virus disease outbreaks. Consequently, the clinical 
presentation of EVD could be refined using statisti-
cal measures, and subclinical EBOV infections lead-
ing to sexual transmission or disease relapse were 
substantiated through clinical observations. In addi-
tion, often-debilitating sequelae in EVD survivors 
were observed longitudinally for the first time. As 
clinical research data on EVD accumulated, the cov-
erage of filovirus disease in ICD-10 was inadequate 
to cover complex clinical presentations of filovirus 
disease. 
[H1] Discussion framework 
[H2] Expert panel and method. Responding to the 
WHO’s public call for input in the development of 
the ICD-11, we assembled a large group of experts 
(the authors) who have treated filovirus-infected 
patients or were heavily involved in organizing the 
treatment of patients to develop ICD-11’s entries on 
filovirus disease. Consensus was obtained by step-
wise, simple-majority, semi-blind voting. The partic-
ipants represented a wide spectrum of scientists 
and health workers of both sexes and from numer-
ous countries, including African nations most affect-
ed by human filovirus infections. 
[H2] Main issues. The ICD-10 recognizes two filo-
viruses diseases: EVD and MVD; however, four ebo-
laviruses (members of the genus Ebolavirus) cause 
disease, with EBOV only being one of them, and two 
marburgviruses (members of the genus Mar-
burgvirus) cause disease, with Marburg virus 
(MARV) being one of them (Table 1). The terms 
‘Ebola virus disease’ and ‘Marburg virus disease’ are 
therefore ambiguous: either the ICD-10 does not 
capture diseases caused by ebolaviruses and mar-
burgviruses other than EBOV and MARV or EVD and 
MVD are cover terms for diseases caused by all ebo-
laviruses and marburgviruses (MARV and Ravn 
virus (RAVV)), requiring authors to specify which 
ebolavirus or marburgvirus caused a particular EVD 
or MVD outbreak. These ambiguities cause major 
confusion in communication among researchers and 
copy editors who are not necessarily familiar with 
the differences between ‘Ebola virus’ and ‘ebo-
lavirus’ or ‘Ebola virus disease due to Ebola virus 
infection’ versus ‘Ebola virus disease due to Bun-
dibugyo virus infection’1. Consequently, the expert 
panel debated whether the EVD and MVD entries in 
ICD-10 should be merged into a single entry, wheth-
er the two terms should be split into several entries 
based on etiologic agents, or whether a hierarchical 
scheme should be adopted to cover both possibili-
ties. 
Although official virus taxonomy may change an-
nually through decisions made by the International 
Committee on Taxonomy of Viruses (ICTV), ICD 
updates and revisions are released at much longer 
intervals. Hence, the ICD cannot keep pace with tax-
onomic developments. Independence of ICD-11 filo-
virus disease names from virus taxonomy consider-
ations was therefore thought to be imperative.  
[H1] Results of expert panel discussions 
A single umbrella term for the disease(s) caused by 
filoviruses is urgently needed as differentiation be-
tween ICD-10’s EVD and MVD on clinical grounds 
alone is impossible. Following the publication of the 
‘WHO Best Practices for the Naming of New Human 
Infectious Diseases’ this parent disease name should 
not contain any geographic locations; people’s 
names; species or class of animal or food; cultural, 
population, industry or occupational references; or 
components that incite undue fear2,3. Furthermore, 
the panel almost unanimously discouraged the use 
of ‘hemorrhagic fever’ for any filovirus-associated 
disease name because ‘hemorrhagic fever’ is not 
unambiguously defined, and the majority of filo-
virus-infected individuals do not develop overt 
hemorrhage. Consequently, healthcare workers 
could misdiagnose filovirus diseases or potentially 
infected individuals may not seek admittance to a 
treatment unit based on the absence of hemorrhage. 
After thorough consideration, ‘Filovirus disease 
(FVD)’ was chosen as the ICD-11 parent disease 
term. Because filoviruses comprise a distinct and 
monophyletic group of viruses, the expert panel felt 
that the prefix ‘filo-’ was unlikely to disappear in the 
near future if taxonomic changes to the virus family 
would be required. Additional subcategories should 
be established to codify diseases caused by filovirus 
that have not yet been associated with filovirus dis-
ease or yet-to-be-discovered novel filoviruses; dis-
eases very likely caused by filoviruses without final 
agent confirmation; and filovirus diseases with ‘un-
usual’ clinical presentation(s). 
The panel advocated for two subcategories to the 
filovirus parent entry for ebolavirus and mar-
burgvirus diseases and recommended, if necessary, 
further subcategorization. The classical distinction 
of ICD-10’s EVD and MVD was felt to be important 
for traditional and familiarity reasons. Furthermore, 
molecular evidence is accumulating that ebolavirus-
es and marburgviruses behave differently in vitro 
and in vivo, suggesting that differences in clinical 
presentation of infections with ebolaviruses or mar-
burgviruses will become evident in the future. ‘Ebo-
la disease (EBOD)’ and ‘Marburg disease (MARD)’ 
were chosen for the major FVD subcategories (Table 
1): FVD due to ebolavirus and marburgvirus infec-
tions, respectively. The WHO naming guidelines 
were not applied in coining these terms because 
both ‘Ebola’ and ‘Marburg’ have been components of 
filovirus disease names since the 1970s and 1960s, 
respectively. The absence of the word ‘virus’ in the 
two disease names makes them taxonomically inde-
pendent and therefore stable.  
The panel then reintroduced the ICD-10 names 
‘Ebola virus disease (EVD)’ and ‘Marburg virus dis-
ease (MVD)’ as EBOD and MARD subcategories be-
cause of their familiarity to the filovirus research 
community but restricted the use of EVD and MVD 
to diseases caused by agents belonging to only one 
species: EBOV (species Zaire ebolavirus), and MARV 
and RAVV (both species Marburg marburgvirus), 
respectively. Two additional EBOD subcategory 
disease terms were added to cover the remaining 
pathogenic filoviruses that have caused more than 
one registered human infection: Bundibugyo virus 
disease (BVD) and Sudan virus disease (SVD). Three 
additional subcategories for both EBOD and MARD 
were proposed: ‘Atypical Ebola/Marburg disease’ 
for EBOD or MARD patients with unusual clinical 
presentation(s); ‘Other specified Ebola/Marburg 
disease’ for EBOD or MARD patients infected with 
ebolaviruses/marburgviruses not covered by BDV, 
EVD and SVD or MVD (for example, disease due to 
Taï Forest virus infection); and ‘Ebola/Marburg 
disease, virus unspecified’ for patients who are sus-
pected to be infected with an ebolavirus or mar-
burgvirus in absence of virus identification. 
The expert panel did not establish a separate cat-
egory for filovirus-induced sequelae in filovirus 
disease survivors (for example, ‘post-Ebola syn-
drome’) as the ICD-11 allows combinatorial coding 
(for example, ‘Atypical Ebola disease’ plus ‘Arthri-
tis’). 
[H1] New official filovirus disease names 
The panel submitted a proposal containing the pro-
posed filovirus disease classification and nomencla-
ture to the WHO’s ICD-11 Proposal Platform in April 
of 2018. After peer review and appropriate revi-
sions, the new filovirus disease classification and 
nomenclature (Table 1, Supplementary Table 4) 
were accepted in May of 2018 and subsequently 
incorporated into the ICD-11 framework 
(https://icd.who.int/browse11/l-m/en). The panel 
recommends that the new filovirus disease names 
and abbreviations be used immediately in forthcom-
ing filovirus publications to ensure a seamless tran-
sition once the ICD-11 is adopted by United Nations 
member states. 
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Table 1. Recommended new human filovirus disease 
classification and nomenclature as accepted by the WHO. 
Main disease 
category.  
 
First disease 
subcategory.  
 
Second disease 
subcategory. 
ICD-11 code and disease name 
1D60 Filovirus 
disease (FVD) 
  
 1D60.0 Ebola 
disease (EBOD) 
 
  1D60.00 
Bundibugyo virus 
disease (BVD)a 
  1D60.01 Ebola virus 
disease (EVD)b 
  1D60.02 Sudan 
virus disease (SVD)c 
  1D60.03 Atypical 
Ebola disease 
  1D60.0Y Other 
specified Ebola 
diseased 
  1D60.0Z Ebola 
disease, virus 
unspecified 
 1D60.1 Marburg 
disease (MARD) 
 
  1D60.10 Marburg 
virus disease 
(MVD)e 
  1D60.11 Atypical 
Marburg disease 
  1D60.1Y Other 
specified Marburg 
disease 
  1D60.1Z Marburg 
disease, virus 
unspecified 
 1D60.Y Other 
specified filovirus 
disease 
 
 1D60.Z Filovirus  
disease, virus 
unspecified 
aCaused by Bundibugyo virus (BDBV); bcaused by Ebola virus 
(EBOV); ccaused by Sudan virus (SUDV); dcaused by, for instance, Taï 
Forest virus (TAFV); ecaused by Marburg virus (MARV) or Ravn virus 
(RAVV). ICD-11; The International [Statistical] Classification of 
Diseases [and Related Health Problems] Revision 11. 
